Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom to Issue More Shares of Stock to SensiGen Shareholders; Settles Claims

NEW YORK (GenomeWeb News) - Sequenom said after the close of the market yesterday that it has agreed to issue additional shares to shareholders of SensiGen to settle certain claims asserted following Sequenom's purchase of SensiGen's assets.

According to a filing with the US Securities and Exchange Commission, Sequenom will issue to certain stockholders 367,547 shares of its common stock. In July, those shareholders had asserted claims for damages of around $1.3 million from an alleged breach of representations and warranties made by Sequenom in its asset purchase agreement.

Earlier in the year, Sequenom had acquired SensiGen's portfolio of AttoSense genetic tests, as well as certain other assets, for $8.7 million in cash and stock.

Sequenom said that it would issue the shares within five days.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.